These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 36724400)

  • 1. Characteristics of patients hospitalized for acute heart failure and discharged from an emergency medicine ward with sacubitril-valsartan: differences with patients in the PIONEER-HF and TRANSITION studies.
    Gabrielli M; Romani GR; Franceschi F
    J Cardiovasc Med (Hagerstown); 2023 Mar; 24(3):203-205. PubMed ID: 36724400
    [No Abstract]   [Full Text] [Related]  

  • 2. Adoption of Sacubitril/Valsartan Among Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction: The Get With The Guidelines-Heart Failure Registry.
    Pierce JB; Li Z; Greiner MA; Lippmann SJ; Hardy NC; Shen X; Stampehl M; Mentz RJ; Allen LA; Peterson PN; Fonarow GC; O'Brien EC; Greene SJ
    Circ Heart Fail; 2023 Jan; 16(1):e010176. PubMed ID: 36314141
    [No Abstract]   [Full Text] [Related]  

  • 3. Representativeness of the PIONEER-HF Clinical Trial Population in Patients Hospitalized With Heart Failure and Reduced Ejection Fraction.
    Fudim M; Sayeed S; Xu H; Matsouaka RA; Heidenreich PA; Velazquez EJ; Yancy CW; Fonarow GC; Hernandez AF; DeVore AD
    Circ Heart Fail; 2020 Apr; 13(4):e006645. PubMed ID: 32248695
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting Cyclic Guanylate Monophosphate in Resistant Hypertension and Heart Failure: Are Sacubitril/Valsartan and Vericiguat Synergistic and Effective in Both Conditions?
    Gallo G; Rubattu S; Volpe M
    High Blood Press Cardiovasc Prev; 2021 Nov; 28(6):541-545. PubMed ID: 34750764
    [No Abstract]   [Full Text] [Related]  

  • 5. Association Between Sacubitril/Valsartan Initiation and Mitral Regurgitation Severity in Heart Failure With Reduced Ejection Fraction: The PROVE-HF Study.
    Januzzi JL; Omar AMS; Liu Y; Murphy S; Butler J; Felker GM; Piña IL; Ward J; Solomon S; Contreras J
    Circulation; 2022 Nov; 146(21):1638-1640. PubMed ID: 36183276
    [No Abstract]   [Full Text] [Related]  

  • 6. Strength in synergy: Cardiometabolic effects of sacubitril/valsartan in heart failure and diabetes.
    Seferović PM; Polovina M; Seferović J; Rosano G
    Int J Cardiol; 2023 Jan; 371():293-294. PubMed ID: 36115444
    [No Abstract]   [Full Text] [Related]  

  • 7. Influence of Ejection Fraction on Outcomes and Efficacy of Sacubitril/Valsartan (LCZ696) in Heart Failure with Reduced Ejection Fraction: The Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF) Trial.
    Solomon SD; Claggett B; Desai AS; Packer M; Zile M; Swedberg K; Rouleau JL; Shi VC; Starling RC; Kozan Ö; Dukat A; Lefkowitz MP; McMurray JJ
    Circ Heart Fail; 2016 Mar; 9(3):e002744. PubMed ID: 26915374
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sacubitril/Valsartan and Rhabdomyolysis: Reanalysis of a Potential Safety Signal.
    Woods RH
    Am J Cardiol; 2022 Jun; 173():145-146. PubMed ID: 35430084
    [No Abstract]   [Full Text] [Related]  

  • 9. Sacubitril/valsartan-treated patients with exacerbated acute heart failure: approaches to care in the emergency department and on the ward.
    Miró Ò; Martín-Sánchez FJ; Jacob J; Herrero-Puente P; Gil V; Llorens P;
    Emergencias; 2019 Dic; 31(6):407-412. PubMed ID: 31777213
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Initiation of Angiotensin-Neprilysin Inhibition After Acute Decompensated Heart Failure: Secondary Analysis of the Open-label Extension of the PIONEER-HF Trial.
    DeVore AD; Braunwald E; Morrow DA; Duffy CI; Ambrosy AP; Chakraborty H; McCague K; Rocha R; Velazquez EJ;
    JAMA Cardiol; 2020 Feb; 5(2):202-207. PubMed ID: 31825471
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sacubitril/Valsartan Initiation and Postdischarge Adherence Among Patients Hospitalized for Heart Failure.
    Carnicelli AP; Lippmann SJ; Greene SJ; Mentz RJ; Greiner MA; Hardy NC; Hammill BG; Shen X; Yancy CW; Peterson PN; Allen LA; Fonarow GC; O'Brien EC
    J Card Fail; 2021 Aug; 27(8):826-836. PubMed ID: 34364659
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical Effectiveness of Sacubitril/Valsartan Among Patients Hospitalized for Heart Failure With Reduced Ejection Fraction.
    Greene SJ; Choi S; Lippmann SJ; Mentz RJ; Greiner MA; Hardy NC; Hammill BG; Luo N; Samsky MD; Heidenreich PA; Laskey WK; Yancy CW; Peterson PN; Curtis LH; Hernandez AF; Fonarow GC; O'Brien EC
    J Am Heart Assoc; 2021 Aug; 10(16):e021459. PubMed ID: 34350772
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Urinary cGMP (Cyclic Guanosine Monophosphate)/BNP (B-Type Natriuretic Peptide) Ratio, Sacubitril/Valsartan, and Outcomes in Heart Failure With Reduced Ejection Fraction: An Analysis of the PARADIGM-HF Trial.
    Butt JH; Ibrahim W; Dewan P; Desai AS; Køber L; Prescott MF; Lefkowitz MP; Rouleau JL; Solomon SD; Zile MR; Packer M; Jhund PS; McMurray JJV
    Circ Heart Fail; 2023 Mar; 16(3):e010111. PubMed ID: 36943907
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of sacubitril/valsartan (LCZ696) in Japanese patients with chronic heart failure and reduced ejection fraction: Rationale for and design of the randomized, double-blind PARALLEL-HF study.
    Tsutsui H; Momomura S; Saito Y; Ito H; Yamamoto K; Ohishi T; Okino N; Guo W
    J Cardiol; 2017 Sep; 70(3):225-231. PubMed ID: 28024961
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Initial clinical experience with the first drug (sacubitril/valsartan) in a new class - angiotensin receptor neprilysin inhibitors in patients with heart failure with reduced left ventricular ejection fraction in Poland.
    Kałużna-Oleksy M; Kolasa J; Migaj J; Pawlak A; Lelonek M; Nessler J; Straburzyńska-Migaj E
    Kardiol Pol; 2018; 76(2):381-387. PubMed ID: 29192956
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sacubitril-valsartan: Hope or hype in the battle against cardiotoxicity due to cancer treatment?
    Yalta K; Gok M; Ozturk C; Yalta T
    Kardiol Pol; 2022; 80(9):958-959. PubMed ID: 35833474
    [No Abstract]   [Full Text] [Related]  

  • 17. Safety of sacubitril/valsartan initiated during hospitalization: data from a non-selected cohort.
    López-Azor JC; Vicent L; Valero-Masa MJ; Esteban-Fernández A; Gómez-Bueno M; Pérez Á; Díez-Villanueva P; De-Juan J; Manuel-Iniesta Á; Bover R; Del Prado S; Martínez-Sellés M
    ESC Heart Fail; 2019 Dec; 6(6):1161-1166. PubMed ID: 31701680
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of sacubitril-valsartan in patients with heart failure: a systematic review and meta-analysis of randomized clinical trials: A PRISMA-compliant article.
    Lin J; Zhou J; Xie G; Liu J
    Medicine (Baltimore); 2021 Dec; 100(52):e28231. PubMed ID: 34967357
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sacubitril/Valsartan: The Newest Addition to the Toolbox for Guideline-Directed Medical Therapy of Heart Failure.
    Rodgers JE
    Am J Med; 2017 Jun; 130(6):635-639. PubMed ID: 28285069
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sacubitril/valsartan vs ACEi/ARB at hospital discharge and 5-year survival in older patients with heart failure with reduced ejection fraction: A decision analysis approach.
    Gilstrap L; Zipkin RJ; Barnes JA; King A; O'Malley AJ; Gaziano TA; Tosteson ANA
    Am Heart J; 2022 Aug; 250():23-28. PubMed ID: 35525261
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.